Margarita Amenedo - Publications

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

Journal: Breast cancer research : BCR

Published: September 10, 2025

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 06, 2025

Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain.

Journal: Cancer treatment and research communications

Published: November 03, 2024

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy.

Journal: Translational lung cancer research

Published: February 04, 2020

Alcohol consumption and lung cancer risk in never smokers: a pooled analysis of case-control studies.

Journal: European journal of public health

Published: November 16, 2017

Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study.

Journal: Cancer letters

Published: July 27, 2017

Small Cell Lung Cancer. Methodology and Preliminary Results of the SMALL CELL Study.

Journal: Archivos de bronconeumologia

Published: January 12, 2017

Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases.

Journal: The European respiratory journal

Published: February 24, 2016

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10).

Journal: Cancer management and research

Published: February 20, 2016

Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia).

Journal: Oncology letters

Published: February 19, 2016

Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.

Journal: Anti-cancer drugs

Published: January 04, 2014

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.

Journal: Cancer chemotherapy and pharmacology

Published: October 03, 2013